C. Roque, H. Solas, G. Fontaine, D. Chêne, L. M. Costagliola et al., Allain and a member from patient' associations. Principal investigators: D. Salmon, F. Dabis Methodology: F. Dabis, M, Project Coordination: M. Winnock, M.A. Loko Clinical Centres

S. Duvivier, A. Boucly, (. D. Neau, P. Morlat, I. Raymond et al., Data collection, management and statistical analyses D

F. Bordeaux, M. Bochet, D. Martino, V. , C. F. Azria et al., 10 APHM hôpital Ste-Marguerite, Service d'Immuno-hématologie clinique Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group, 9 Hôpital de l'Archet-Descartes, INSERM U567-CNRS (UMR 8104), pp.1054-1058, 1999.

C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet et al., Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The ???Mortalit?? 2000 and 2005??? Surveys (ANRS EN19 and Mortavic), JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.48, issue.5, pp.590-598, 2000.
DOI : 10.1097/QAI.0b013e31817efb54

E. Rosenthal, D. Salmon-ceron, C. Lewden, V. Bouteloup, G. Pialoux et al., Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalit?? 2005 survey, ANRS EN19), the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19), pp.282-289, 1995.
DOI : 10.1111/j.1468-1293.2008.00686.x

D. Salmon-ceron, C. Lewden, P. Morlat, S. Bevilacqua, E. Jougla et al., Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol, Journal of Hepatology, vol.42, issue.6, pp.799-805, 2005.
DOI : 10.1016/j.jhep.2005.01.022

R. Weber, C. Sabin, N. Friis-moller, P. Reiss, W. El-sadr et al., Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study, Arch Intern Med, vol.166, pp.1632-1641, 2006.

M. Grishchenko, R. Grieve, M. Sweeting, D. Angelis, D. Thomson et al., Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice, International Journal of Technology Assessment in Health Care, vol.95, issue.02, pp.171-180, 2009.
DOI : 10.1002/jmv.10406

M. Fried, M. Shiffman, K. Reddy, C. Smith, G. Marinos et al., Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.347, issue.13, pp.975-982, 2002.
DOI : 10.1056/NEJMoa020047

M. Manns, J. Mchutchison, S. Gordon, V. Rustgi, M. Shiffman et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-965, 2001.
DOI : 10.1016/S0140-6736(01)06102-5

S. Hadziyannis, H. Sette, . Jr, T. Morgan, V. Balan et al., Peginterferon-??2a and Ribavirin Combination Therapy in Chronic Hepatitis C, Annals of Internal Medicine, vol.140, issue.5, pp.346-355, 2004.
DOI : 10.7326/0003-4819-140-5-200403020-00010

M. Lagging, R. Wejstal, I. Uhnoo, B. Gerden, B. Fischler et al., Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations, Scandinavian Journal of Infectious Diseases, vol.48, issue.6-7, pp.389-402, 2009.
DOI : 10.1056/NEJMoa0807650

J. Rockstroh, S. Bhagani, Y. Benhamou, R. Bruno, S. Mauss et al., European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults, HIV Medicine, vol.47, issue.2, pp.82-88, 2008.
DOI : 10.1097/01.qai.0000167158.90722.73

J. Morrill, M. Shrestha, and R. Grant, Barriers to the treatment of hepatitis C, Journal of General Internal Medicine, vol.26, issue.8, pp.754-758, 2005.
DOI : 10.1111/j.1525-1497.2005.0161.x

J. Cox, L. Graves, E. Marks, C. Tremblay, R. Stephenson et al., Knowledge, attitudes and behaviours associated with the provision of hepatitis C care by Canadian family physicians, Journal of Viral Hepatitis, vol.21, issue.Suppl. C, pp.332-340, 2011.
DOI : 10.1111/j.1365-2893.2010.01426.x

L. Gheorghe, O. Pascu, E. Ceausu, I. Csiki, S. Iacob et al., Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009, J Gastrointestin Liver Dis, vol.19, pp.161-167, 2010.

M. Melia, A. Muir, J. Mccone, M. Shiffman, J. King et al., Racial differences in hepatitis C treatment eligibility, Hepatology, vol.106, issue.3 Suppl 3, pp.70-78, 2011.
DOI : 10.1002/hep.24358
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736356

A. Sanvisens, D. Fuster, I. Serra, J. Tor, C. Tural et al., Estimated Liver Fibrosis and its Impact on All-Cause Mortality of HCV-Monoinfected and HCV/HIV-Coinfected Drug Users, Current HIV Research, vol.9, issue.4, pp.256-262, 2011.
DOI : 10.2174/157016211796320298

C. Treloar, J. Newland, J. Rance, and M. Hopwood, Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals, Journal of Viral Hepatitis, vol.28, issue.2, pp.839-844, 2010.
DOI : 10.1111/j.1365-2893.2009.01250.x

E. Bini, N. Brau, S. Currie, H. Shen, B. Anand et al., Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection, The American Journal of Gastroenterology, vol.36, issue.5, pp.1772-1779, 2005.
DOI : 10.1002/hep.20119

F. Kanwal, T. Hoang, B. Spiegel, S. Eisen, J. Dominitz et al., Predictors of treatment in patients with chronic hepatitis C infection-Role of patient versus nonpatient factors, Hepatology, vol.13, issue.9 Suppl, pp.1741-1749, 2007.
DOI : 10.1002/hep.21927

Y. Falck-ytter, H. Kale, K. Mullen, S. Sarbah, L. Sorescu et al., Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C, Annals of Internal Medicine, vol.136, issue.4, pp.288-292, 2002.
DOI : 10.7326/0003-4819-136-4-200202190-00008

H. Groom, E. Dieperink, D. Nelson, J. Garrard, J. Johnson et al., Outcomes of a Hepatitis C Screening Program at a Large Urban VA Medical Center, Journal of Clinical Gastroenterology, vol.42, issue.1, pp.97-106, 2008.
DOI : 10.1097/MCG.0b013e31802dc56f

R. Hallinan, A. Byrne, K. Agho, and G. Dore, Referral for chronic hepatitis C treatment from a drug dependency treatment setting, Drug and Alcohol Dependence, vol.88, issue.1, pp.49-53, 2007.
DOI : 10.1016/j.drugalcdep.2006.09.018

A. Butt, A. Justice, M. Skanderson, M. Rigsby, C. Good et al., Rate and predictors of treatment prescription for hepatitis C, Gut, vol.56, issue.3, pp.385-389, 2007.
DOI : 10.1136/gut.2006.099150

M. Jauffret-roustide, L. Oudaya, M. Rondy, L. Strat, Y. Couturier et al., Représentations du traitement de l'hépatite C chez les usagers de drogues, Enquête InVS-ANRS Coquelicot, pp.20-21213, 2004.

S. Arora, S. Kalishman, K. Thornton, D. Dion, G. Murata et al., Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care, Hepatology, vol.134, issue.Suppl. 1, pp.1124-1133, 2010.
DOI : 10.1002/hep.23802

S. Arora, K. Thornton, G. Murata, P. Deming, S. Kalishman et al., Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers, New England Journal of Medicine, vol.364, issue.23, pp.2199-2207, 2011.
DOI : 10.1056/NEJMoa1009370

C. Lindenburg, F. Lambers, A. Urbanus, J. Schinkel, P. Jansen et al., Hepatitis C testing and treatment among active drug users in Amsterdam, European Journal of Gastroenterology & Hepatology, vol.23, issue.1, pp.23-31, 2011.
DOI : 10.1097/MEG.0b013e328340c451

A. Mocroft, J. Rockstroh, V. Soriano, O. Kirk, J. Viard et al., Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C, Scandinavian Journal of Infectious Diseases, vol.19, issue.11-12, pp.1092-1097, 2006.
DOI : 10.1080/00365540600786515

C. Cooper, C. Giordano, D. Mackie, and E. Mills, Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision, Therapeutics and Clinical Risk Management, vol.6, pp.207-212, 2010.
DOI : 10.2147/TCRM.S9951

P. Cacoub, E. Rosenthal, P. Halfon, D. Sene, C. Perronne et al., Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life, Journal of Viral Hepatitis, vol.19, issue.3, pp.678-682, 2006.
DOI : 10.1097/00002030-200401020-00001

C. Fleming, D. Craven, D. Thornton, S. Tumilty, and D. Nunes, Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment, Clinical Infectious Diseases, vol.36, issue.1, pp.97-100, 2003.
DOI : 10.1086/344907

D. Fishbein, Y. Lo, J. Reinus, M. Gourevitch, and R. Klein, Factors Associated With Successful Referral For Clinical Care of Drug Users With Chronic Hepatitis C Who Have or Are At Risk For HIV Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.37, issue.3, pp.1367-1375, 2004.
DOI : 10.1097/01.qai.0000131932.21612.49

O. Nguyen, G. Dore, J. Kaldor, and M. Hellard, Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study, International Journal of Drug Policy, vol.18, issue.5, pp.447-451, 2007.
DOI : 10.1016/j.drugpo.2007.01.007

D. Rey, M. Carrieri, B. Spire, S. Loubiere, P. Dellamonica et al., Factors Associated with Liver Biopsy Performance in HCV-HIV Coinfected Injecting Drug Users With HCV Viremia: Results From a Five-Year Longitudinal Assessment, Journal of Urban Health: Bulletin of the New York Academy of Medicine, vol.81, issue.1, pp.48-57, 2004.
DOI : 10.1093/jurban/jth087

A. Restrepo, T. Johnson, D. Widjaja, L. Yarmus, K. Meyer et al., The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre, Journal of Viral Hepatitis, vol.165, issue.1, pp.86-90, 2005.
DOI : 10.1016/S0140-6736(01)06102-5

S. Mehta, G. Lucas, L. Mirel, M. Torbenson, Y. Higgins et al., Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic, AIDS, vol.20, issue.18, pp.2361-2369, 2006.
DOI : 10.1097/QAD.0b013e32801086da

H. Gidding, M. Law, J. Amin, G. Macdonald, J. Sasadeusz et al., Predictors of deferral of treatment for hepatitis C infection in Australian clinics, Med J Aust, vol.194, pp.398-402, 2011.

V. Perut, C. Labalette, P. Sogni, I. Ferrand, D. Salmon-ceron et al., Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition?, Drug and Alcohol Dependence, vol.104, issue.1-2, pp.78-83, 2009.
DOI : 10.1016/j.drugalcdep.2009.04.002

J. Grebely, J. Bryant, P. Hull, M. Hopwood, Y. Lavis et al., Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia, Journal of Viral Hepatitis, vol.22, issue.3, pp.104-116, 2011.
DOI : 10.1111/j.1365-2893.2010.01370.x

M. Loko, D. Salmon, P. Carrieri, M. Winnock, M. Mora et al., The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010, BMC Infectious Diseases, vol.33, issue.Suppl 2, p.303, 2006.
DOI : 10.1007/s10900-007-9083-3
URL : https://hal.archives-ouvertes.fr/pasteur-01070193

L. Castera, J. Vergniol, J. Foucher, L. Bail, B. Chanteloup et al., Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C, Gastroenterology, vol.128, issue.2, pp.343-350, 2005.
DOI : 10.1053/j.gastro.2004.11.018

R. Fuhrer and F. Rouillon, La version française de l'échelle CES-D. Description and translation of the autoevaluation scale, Psychiatrie et Psychobiologie, vol.4, pp.163-166, 1989.

A. Justice, W. Holmes, A. Gifford, L. Rabeneck, R. Zackin et al., Development and validation of a self-completed HIV symptom index, Journal of Clinical Epidemiology, vol.54, issue.12, pp.54-77, 2001.
DOI : 10.1016/S0895-4356(01)00449-8

M. Bohn, T. Babor, and H. Kranzler, The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings., Journal of Studies on Alcohol, vol.56, issue.4, pp.423-432, 1995.
DOI : 10.15288/jsa.1995.56.423

P. Gache, P. Michaud, U. Landry, C. Accietto, S. Arfaoui et al., The Alcohol Use Disorders Identification Test (AUDIT) as a Screening Tool for Excessive Drinking in Primary Care: Reliability and Validity of a French Version, Alcoholism: Clinical & Experimental Research, vol.129, issue.5, pp.2001-2007, 2005.
DOI : 10.1111/j.1360-0443.1997.tb03652.x

J. Heeb and G. Gmel, Measuring alcohol consumption: A comparison of graduated frequency, quantity frequency, and weekly recall diary methods in a general population survey, Addictive Behaviors, vol.30, issue.3, pp.403-413, 2005.
DOI : 10.1016/j.addbeh.2004.04.022

S. Van-buuren, H. Boshuizen, and D. Knook, Multiple imputation of missing blood pressure covariates in survival analysis, pp.681-694, 1999.

D. Swan, J. Long, O. Carr, J. Flanagan, H. Irish et al., Barriers to and Facilitators of Hepatitis C Testing, Management, and Treatment Among Current and Former Injecting Drug Users: A Qualitative Exploration, AIDS Patient Care and STDs, vol.24, issue.12, pp.753-762, 2010.
DOI : 10.1089/apc.2010.0142

A. Doab, C. Treloar, and G. Dore, Knowledge and Attitudes about Treatment for Hepatitis C Virus Infection and Barriers to Treatment among Current Injection Drug Users in Australia, Clinical Infectious Diseases, vol.40, issue.s5, pp.40-313, 2005.
DOI : 10.1086/427446

C. Bova, L. Ogawa, and S. Sullivan-bolyai, Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV Infection, Journal of the Association of Nurses in AIDS Care, vol.21, issue.1, pp.63-74, 2010.
DOI : 10.1016/j.jana.2009.07.009

C. Fleming, S. Tumilty, J. Murray, and D. Nunes, Challenges in the Treatment of Patients Coinfected with HIV and Hepatitis C Virus: Need for Team Care, Clinical Infectious Diseases, vol.40, issue.s5, pp.40-349, 2005.
DOI : 10.1086/427452

M. Baum, D. Jayaweera, R. Duan, S. Sales, S. Lai et al., Quality of Life, Symptomatology and Healthcare Utilization in HIV/HCV Co-Infected Drug Users in Miami, Journal of Addictive Diseases, vol.72, issue.2, pp.37-48, 2008.
DOI : 10.1111/j.1468-1293.2005.00291.x

F. Marcellin, M. Preau, P. Dellamonica, I. Ravaux, P. Kurkdji et al., Adding HCV Treatment to HIV Treatment in HIV-HCV Coinfected Patients: The Impact on the Different Dimensions of Fatigue and Self-Reported Side Effects, Journal of Pain and Symptom Management, vol.34, issue.4, pp.413-421, 2007.
DOI : 10.1016/j.jpainsymman.2006.12.014

F. Marcellin, M. Preau, I. Ravaux, P. Dellamonica, B. Spire et al., Self-Reported Fatigue and Depressive Symptoms as Main Indicators of the Quality of Life (QOL) of Patients Living with HIV and Hepatitis C: Implications for Clinical Management and Future Research, HIV Clinical Trials, vol.17, issue.1, pp.320-327, 2007.
DOI : 10.1097/01.psy.0000124757.10167.b1

. Salmon-ceron, http://www.biomedcentral.com/1472-6963/12/59 treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users, Health Services Research Addiction, vol.12, issue.107, pp.59152-159, 2012.

A. Walley, M. White, M. Kushel, Y. Song, and J. Tulsky, Knowledge of and interest in hepatitis C treatment at a methadone clinic, Journal of Substance Abuse Treatment, vol.28, issue.2, pp.181-187, 2005.
DOI : 10.1016/j.jsat.2004.12.004

P. Cacoub, P. Halfon, E. Rosenthal, G. Pialoux, Y. Benhamou et al., Treatment of hepatitis C virus in human immunodeficiency virus infected patients in ???real life???: Modifications in two large surveys between 2004 and 2006, Journal of Hepatology, vol.48, issue.1, pp.35-42, 2004.
DOI : 10.1016/j.jhep.2007.07.028

D. Nunes, R. Saitz, H. Libman, D. Cheng, J. Vidaver et al., Barriers to Treatment of Hepatitis C in HIV/HCV-Coinfected Adults with Alcohol Problems, Alcoholism: Clinical and Experimental Research, vol.72, issue.9, pp.1520-1526, 2006.
DOI : 10.1056/NEJMoa040842

P. Roux, M. Carrieri, V. Villes, P. Dellamonica, I. Poizot-martin et al., The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study, Addiction, vol.38, issue.11, pp.1828-1836, 2008.
DOI : 10.1111/j.1360-0443.2008.02323.x

S. Darke, Self-report among injecting drug users: A review, Drug and Alcohol Dependence, vol.51, issue.3, pp.253-263, 1998.
DOI : 10.1016/S0376-8716(98)00028-3

M. Grignon, M. Perronnin, and J. Lavis, Does free complementary health insurance help the poor to access health care? Evidence from France, Health Economics, vol.13, issue.2, pp.203-219, 2008.
DOI : 10.1002/hec.1250